[New and older pharmaceuticals influencing insulin secretion].
The author briefly recapitulates the physiology of insulin secretion and pathophysiology with type II diabetes mellitus. Besides sulfonylurea secretagogues and glinides practically used in the long term, the author points out new possibilities of influencing insulin secretion by way of incretin mimetics and gliptins.
Olsovský
J
J
Diabetologické centrum II. interní kliniky Lékarské fakulty MU a FN u sv. Anny Brno. jindrich.olsovsky@fnusa.cz
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology*; D052216:Glucagon-Like Peptide 1 / Q000494:pharmacology / Q000627:therapeutic use; D005947:Glucose / Q000378:metabolism; D006801:Humans; D054795:Incretins / Q000494:pharmacology / Q000627:therapeutic use; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D013453:Sulfonylurea Compounds / Q000494:pharmacology / Q000627:therapeutic use
D054795:Incretins; D007328:Insulin; D013453:Sulfonylurea Compounds; D052216:Glucagon-Like Peptide 1; D005947:Glucose